Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Butcher

Showing results (261-270 of 275) with videos related to

Pageof 28
Sort By:
Journal of Medicinal Chemistry|January 28, 2015
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitorsJ Michael Ellis, Michael D Altman, Alan Bass, et al.
Critical Care Medicine|October 7, 2022
Patient and Caregiver-Derived Health Service Improvements for Better Critical Care RecoveryKimberley J Haines, Nina Leggett, Elizabeth Hibbert, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of AsthmaXianhai Huang, Jason Brubaker, Wei Zhou, et al.
Critical Care Medicine|June 6, 2021
Transitions of Care After Critical Illness-Challenges to Recovery and Adaptive Problem SolvingKimberley J Haines, Elizabeth Hibbert, Nina Leggett, et al.
Journal of Medicinal Chemistry|June 23, 1999
Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinaseN J Liverton, J W Butcher, C F Claiborne, et al.
American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses|February 10, 2021
Establishing a Peer Support Program for Survivors of COVID-19: A Report From the Critical and Acute Illness Recovery OrganizationAluko A Hope, Andrea Annie Johnson, Joanne McPeake, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
Critical Care Medicine|June 27, 2019
Enablers and Barriers to Implementing ICU Follow-Up Clinics and Peer Support Groups Following Critical Illness: The Thrive CollaborativesKimberley J Haines, Joanne McPeake, Elizabeth Hibbert, et al.
Pageof 28

Showing results (261-270 of 275) with videos related to

Sort By:
Pageof 28
Journal of Medicinal Chemistry|January 28, 2015
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitorsJ Michael Ellis, Michael D Altman, Alan Bass, et al.
Critical Care Medicine|October 7, 2022
Patient and Caregiver-Derived Health Service Improvements for Better Critical Care RecoveryKimberley J Haines, Nina Leggett, Elizabeth Hibbert, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of AsthmaXianhai Huang, Jason Brubaker, Wei Zhou, et al.
Critical Care Medicine|June 6, 2021
Transitions of Care After Critical Illness-Challenges to Recovery and Adaptive Problem SolvingKimberley J Haines, Elizabeth Hibbert, Nina Leggett, et al.
Journal of Medicinal Chemistry|June 23, 1999
Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinaseN J Liverton, J W Butcher, C F Claiborne, et al.
American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses|February 10, 2021
Establishing a Peer Support Program for Survivors of COVID-19: A Report From the Critical and Acute Illness Recovery OrganizationAluko A Hope, Andrea Annie Johnson, Joanne McPeake, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
Critical Care Medicine|June 27, 2019
Enablers and Barriers to Implementing ICU Follow-Up Clinics and Peer Support Groups Following Critical Illness: The Thrive CollaborativesKimberley J Haines, Joanne McPeake, Elizabeth Hibbert, et al.
Pageof 28